Manufacturer
AbbVie Ltd(UNITED STATES)
Registraction Number
MAL19106013ACRZ
Contents:
• Active Ingredient: Olaparib 150 mg per tablet
• Inactive Ingredients: Copovidone, Colloidal anhydrous silica, Mannitol, Sodium stearyl fumarate (tablet core); Hypromellose, Macrogol 400, Titanium dioxide (E171), Iron oxide yellow (E172), Iron oxide black (E172) (150 mg tablets only)
Indications:
Lynparza is indicated for the treatment of several types of cancers, including:
• Ovarian Cancer: Maintenance treatment for adult patients with advanced BRCA1/2-mutated high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer.
• Breast Cancer: Adjuvant treatment for adults with germline BRCA1/2-mutations who have been previously treated with chemotherapy.
• Pancreatic Cancer: Maintenance treatment for adult patients with metastatic adenocarcinoma of the pancreas and germline BRCA1/2-mutations.
• Prostate Cancer: Treatment for adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations.
Instructions:
• Dosage: The recommended dose is 300 mg (two 150 mg tablets) taken orally twice daily with or without food.
• Administration: Take the tablets consistently at the same time each day.
• Monitoring: Treatment should be initiated and supervised by a physician experienced in the use of anticancer therapies.
• Adjustments: For moderate renal impairment, the dose should be reduced to 200 mg twice daily.
Malaysia
